Annexon Appoints New Chief Medical Officer
Ticker: ANNX · Form: 8-K · Filed: Jun 25, 2024 · CIK: 1528115
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Annexon just hired a new CMO, Dr. David Rick. Big move for their drug pipeline.
AI Summary
On June 25, 2024, Annexon, Inc. filed an 8-K report detailing the appointment of Dr. David E. Rick as Chief Medical Officer, effective June 24, 2024. Dr. Rick brings extensive experience in clinical development and medical affairs, previously holding leadership roles at companies like Genentech and Alexion Pharmaceuticals.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's strategic direction in drug development and clinical trials.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the executive level like CMO, can signal shifts in strategy or operational focus, introducing a degree of uncertainty.
Key Players & Entities
- Annexon, Inc. (company) — Registrant
- Dr. David E. Rick (person) — Newly appointed Chief Medical Officer
- June 25, 2024 (date) — Filing date of the 8-K report
- June 24, 2024 (date) — Effective date of Dr. Rick's appointment
- Genentech (company) — Previous employer of Dr. Rick
- Alexion Pharmaceuticals (company) — Previous employer of Dr. Rick
FAQ
Who is the new Chief Medical Officer at Annexon, Inc.?
Dr. David E. Rick has been appointed as the new Chief Medical Officer.
When was Dr. David E. Rick's appointment effective?
Dr. Rick's appointment was effective as of June 24, 2024.
What is the filing date of this 8-K report?
The 8-K report was filed on June 25, 2024.
What is Annexon, Inc.'s principal executive office address?
Annexon, Inc.'s principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.
What prior experience does Dr. David E. Rick bring to Annexon?
Dr. Rick has prior leadership experience in clinical development and medical affairs at companies such as Genentech and Alexion Pharmaceuticals.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-06-25 17:14:51
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Mar
Filing Documents
- d822308d8k.htm (8-K) — 24KB
- d822308dex991.htm (EX-99.1) — 28KB
- g822308g0625235854026.jpg (GRAPHIC) — 3KB
- 0001193125-24-167962.txt ( ) — 186KB
- annx-20240625.xsd (EX-101.SCH) — 3KB
- annx-20240625_lab.xml (EX-101.LAB) — 18KB
- annx-20240625_pre.xml (EX-101.PRE) — 11KB
- d822308d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated June 25, 2024, titled "Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting." 104.1 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 25, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer